Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer (Q43805357)

27 November 2017

Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer (English)

1 reference

27 November 2017

1 reference

Alexandra Voutsina

1

1 reference

27 November 2017

Maria Tzardi

2

1 reference

27 November 2017

Aristea Kalikaki

3

1 reference

27 November 2017

Zafeiris Zafeiriou

4

1 reference

27 November 2017

Elsa Papadimitraki

5

1 reference

27 November 2017

Michael Papadakis

6

1 reference

27 November 2017

Dimitris Mavroudis

7

1 reference

27 November 2017

Vassilis Georgoulias

8

1 reference

27 November 2017

31 August 2012

1 reference

27 November 2017

1 reference

27 November 2017

26

1 reference

27 November 2017

2

1 reference

27 November 2017

302-313

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.150

27 November 2017

0 references

cites work

Biomarker-based prediction of response to therapy for colorectal cancer: current perspective

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Evolving treatment of advanced colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Cancer: Genomics of metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Comparative lesion sequencing provides insights into tumor evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Cancer metastasis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Parallel progression of primary tumours and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

A cross-talk between oncogenic Ras and tumor suppressor PTEN through FAK Tyr861 phosphorylation in NIH/3T3 mouse embryonic fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PTEN loss accelerates KrasG12D-induced pancreatic cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Essential role for nuclear PTEN in maintaining chromosomal integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

A robust immunohistochemical assay for detecting PTEN expression in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Clinical significance of tumor suppressor PTEN in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

MET signalling in primary colon epithelial cells leads to increased transformation irrespective of aberrant Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

MET expression and amplification in patients with localized gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Cancer biology: Role of nuclear PTEN revealed

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Melanoma: Early exposure is inflammatory

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

Poor Survival Associated with theBRAFV600E Mutation in Microsatellite-Stable Colon Cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.150

7 January 2021

10.1038/MODPATHOL.2012.150

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

0 references

1 reference